Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07153471 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Name: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee — clinical trial record (NCT07153471)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATTAIN-OA PAIN

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2025-09-15

View on ClinicalTrials.gov ↗

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Amendment history 1 change detected by DataLookout

2026-09-09

Trial sites reduced: 96 → 88 locations

Trial Details

NCT Number	NCT07153471
Lead Sponsor	Eli Lilly and Company
Conditions	Osteoarthritis
Enrollment	800 participants
Start Date	2025-09-15
Primary Completion	2028-04 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-08